Diabetes Mellitus Clinical Trial
Official title:
Feet First: Increasing Activity Without Increasing the Risk of Foot Ulcers in People With Diabetes and Insensate Feet
The role of weight-bearing physical activity in the development of diabetic foot ulcers
remains poorly understood. Regular participation in moderately intense physical activity
(e.g. brisk walking ) reduces 8-year cardiovascular mortality in those with diabetes
mellitus by over 30%. The American Diabetes Association (ADA) recommends at least 30 minutes
of daily moderate intensity activity for people with diabetes. However, the ADA recommends
that people with diabetes and insensate feet, which affects up to 40% of those with
diabetes, should limit their walking because of concerns that walking could increase the
risk of foot ulcers and amputation. Firm evidence is lacking to support these concerns; in
fact, while a research fellow I conducted an observational study that showed daily
weight-bearing activity may reduce the risk of foot ulceration among people with diabetic
foot problems. A controlled clinical trial is needed to study these issues further.
The present study is a randomized controlled trial in 100 older adults with diabetes and
insensate feet, 50 of whom will participate in an individually-tailored behavior-change
intervention called "Feet First", and 50 of whom will be controls. The intervention is based
on the extensively-tested CHAMPS model used by the Robert Wood Johnson Foundation's Active
for Life Program. Feet First extends the target population beyond older adults generally to
people with insensate feet due to diabetic peripheral neuropathy.
The specific aims of the study are:
- To determine whether Feet First intervention subjects achieve a greater increase in
weight-bearing activity than control subjects, and
- To obtain preliminary evidence on intervention subjects' foot outcomes (foot function,
foot-related self-care, and risk of foot ulcers), compared to control subjects.
Physical activity is a vital component of self-management for patients with diabetes
mellitus, yet there are special problems in patients whose disease is complicated by
insensate feet (i.e. loss of protective sensation caused by diabetic distal symmetric
sensory peripheral neuropathy). Foot ulcers develop in 15% of the 17 million people in the
United States with diabetes mellitus, and contribute to 84% of foot or toe amputations. Foot
ulcer risk is very high among those with insensate feet. Although the roles of neuropathy,
plantar foot pressure, and footwear in foot ulcers have been extensively studied, the
independent role of physical activity has not. The overall goal of this study is to
determine whether a "lifestyle" physical activity intervention, based on the Second
Community Healthy Activities Model Program for Seniors (CHAMPS II), which we call FEET
FIRST, can be used to safely increase moderate-intensity physical activity (achieving at
least 40% of maximal oxygen consumption, as in walking briskly) among people with diabetes
and insensate feet. "Lifestyle" physical activity interventions help participants to
accumulate at least 30 minutes of self-selected activities in short bouts during the day.
CHAMPS II effectively and safely increased physical activity in sedentary older adults with
multiple chronic illnesses.
Substantial research has also found that people with diabetic peripheral neuropathy are also
at increased risk of falls. Diabetic peripheral neuropathy also leads to postural
instability, i.e. impairment in measures of functional dynamic balance. Moreover, this
instability worsens with age. People with diabetic peripheral neuropathy in particular tend
to have ankle instability due to decreased proprioception, making them less able to rapidly
recover balance during sudden ankle dorsiflexion, inversion or eversion when walking on
uneven surfaces.
There is ample evidence that promotion of an active lifestyle and specific exercises
targeting endurance, strength and balance improves reduces functional decline in the
elderly, and that home-based exercise programs effectively decrease fall risk in the elderly
as well. One small, non-randomized trial found preliminary evidence that a 3-week
intervention that focused on ankle strength improved balance measures in those with diabetic
peripheral neuropathy. However, no randomized studies have investigated the effect of a
physical activity intervention on fall risk in community-dwelling people with diabetic
peripheral neuropathy, who may also be at increased risk of cutaneous injuries (i.e. foot
lesions) during weight-bearing activity. Before we unequivocally recommend to people with
diabetic peripheral neuropathy that they engage in exercise, we need to determine that this
will be safe for their feet, and not increase fall risk.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03743779 -
Mastering Diabetes Pilot Study
|
||
Completed |
NCT03786978 -
Pharmaceutical Care in the Reduction of Readmission Rates in Diabetes Melitus
|
N/A | |
Completed |
NCT01804803 -
DIgital Assisted MONitoring for DiabeteS - I
|
N/A | |
Completed |
NCT05039970 -
A Real-World Study of a Mobile Device-based Serious Health Game on Session Attendance in the National Diabetes Prevention Program
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Completed |
NCT04068272 -
Safety of Bosentan in Type II Diabetic Patients
|
Phase 1 | |
Completed |
NCT03243383 -
Readmission Prevention Pilot Trial in Diabetes Patients
|
N/A | |
Completed |
NCT03730480 -
User Performance of the CONTOUR NEXT and CONTOUR TV3 Blood Glucose Monitoring System (BGMS)
|
N/A | |
Recruiting |
NCT02690467 -
Efficacy, Safety and Acceptability of the New Pen Needle 34gx3,5mm.
|
N/A | |
Completed |
NCT02229383 -
Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus
|
Phase 3 | |
Completed |
NCT06181721 -
Evaluating Glucose Control Using a Next Generation Automated Insulin Delivery Algorithm in Patients With Type 1 and Type 2 Diabetes
|
N/A | |
Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
Recruiting |
NCT04489043 -
Exercise, Prediabetes and Diabetes After Renal Transplantation.
|
N/A | |
Withdrawn |
NCT03319784 -
Analysis for NSAID VS Corticosteroid Shoulder Injection in Diabetic Patients
|
Phase 4 | |
Completed |
NCT03542084 -
Endocrinology Auto-Triggered e-Consults
|
N/A | |
Completed |
NCT02229396 -
Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo
|
Phase 3 | |
Recruiting |
NCT05544266 -
Rare and Atypical Diabetes Network
|
||
Completed |
NCT01892319 -
An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry
|
||
Completed |
NCT05031000 -
Blood Glucose Monitoring Systems: Discounter Versus Brand
|
N/A | |
Recruiting |
NCT04039763 -
RT-CGM in Young Adults at Risk of DKA
|
N/A |